

REVENIO

Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group Corporation, Stock Exchange Release, May 11, 2022 at 3.00 p.m. (EEST)

Transfer of the Company's own shares

Revenio Group Corporation has on May 11, 2022 transferred 2,055 shares (REG1V) to the members of the Board of Directors as part of the remuneration of the Board.

Revenio Group Corporation's AGM decided on April 8, 2022 that approximately 40 per cent of the Board members' annual remuneration (gross) will be settled in the form of the company's shares held in its treasury, however not exceeding a maximum of 3,200 shares in total, while approximately 60 per cent will consist of a monetary payment. The AGM decided that the Chairman of the Board be entitled to an annual emolument of EUR 60,000, the Board Members be entitled to an annual emolument of EUR 30,000, the chair of the Audit Committee be entitled to an annual emolument of EUR 15,000, the chair of the Nomination and Remuneration Committee be entitled to an annual emolument of EUR 10,000, and the members of the Board Committees be entitled to an annual emolument of EUR 5,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- March 31, 2022.

As a result of these transfers, the share-based board member fees have been completely settled for the year 2022. Revenio Group Corporation now holds a total of 115,704 of its own shares.

Revenio Group Corporation
Board of Directors

For further information, please contact

Robin Pulkkinen, CFO, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

Distribution

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

Revenio Group in brief

REVENIO

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Transfer of the Company's own shares](#)